. 2019 Feb 25;2019:9276953. doi: 10.1155/2019/9276953

Table 3.

Acute hypoglycemic effect of the isolated compounds.

	Glucose levels in the maltose curve [mg/dl]
Group/Time (min.)	T0	T60	T120	T180
Normoglycemic control	106 ± 5 ^b	114 ± 9^b	110 ± 7^b	105 ± 5^b

Hyperglycaemic control	196 ± 7	191 ± 7	187 ± 3	194 ± 6

Hyperglycemic + glibenclamide	192 ± 8	118 ± 10^a,b	107 ± 7^a,b	106 ± 9^a,b
5 mg/kg	192 ± 8	118 ± 10^a,b	107 ± 7^a,b	106 ± 9^a,b

β-Sitosterol-3-O-β-D-glucopyranoside. 72 mg/kg	186 ± 6	203 ± 5	172 ± 2	156 ± 7^b

Cirsiliol 4′-O-glucoside	194 ± 5	179 ± 8^a	160 ± 10^a,b	133 ± 14^a,b
1.8 mg/kg	194 ± 5	179 ± 8^a	160 ± 10^a,b	133 ± 14^a,b

ρ-Coumaric acid	187 ± 8	198 ± 7	180 ± 7^a	166 ± 9^a
3.63 mg/kg	187 ± 8	198 ± 7	180 ± 7^a	166 ± 9^a

The values represent the mean ± SEM. In the same row: a indicates statistically significant differences compared with time 0. In the same column: b indicates statistically significant differences compared with the diabetic control group; p < 0.05, n = 3.